Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 2, 2012

Sanofi Pasteur’s Quadrivalent Flu Vaccine Succeeds in Phase III Pediatric Study

  • Sanofi Pasteur reported positive data from a Phase III study comparing its quadrivalent influenza vaccine (QIV) to the firm’s approved trivalent vaccine Fluzone®, in infants and children aged 6 months to 8 years. The trial included over 4,300 children, and demonstrated the noninferiority of QIV when compared with vaccination using either the licensed trivalent inactivated vaccine (TIV) Fluzone, which contains two influenza A strains and the Victoria-lineage B strain, or a TIV containing the two licensed A strains plus the alternate (Yamagata) B lineage strain.

    Seasonal trivalent influenza vaccines currently contain two A strains and one B strain, but two distinct B lineage strains have co-circulated over the last decade with varying prevlance, which makes it hard to predict which will predominate in a given year, Sanofi Pasteur explains. Moreover, the firm claims, about 50% of the time the B-lineage strain selected for the annual vaccine hasn’t matched the strain predominating during that season.

    “We believe that a quadrivalent Fluzone vaccine could provide an important public health benefit for people of all ages by providing coverage against an extra B virus strain of influenza,” comments David Greenberg, M.D., senior director for U.S. scientific and medical affairs at Sanofi Pasteur. “Influenza B is responsible for a substantial burden of disease and influenza-associated complications and hospitalizations in children.” 

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »